(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 November 2012 (29.11.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/160358 A1

(51) International Patent Classification:
A61K 31/05 (2006.01) *A61K 31/352* (2006.01)
A61K 31/185 (2006.01) *A61P 25/02* (2006.01)

(21) International Application Number:
PCT/GB2012/051129

(22) International Filing Date:
18 May 2012 (18.05.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1108506.5 20 May 2011 (20.05.2011) GB

(71) Applicants *(for all designated States except US)*: **GW PHARMA LIMITED** [GB/GB]; Porton Down Science Park, Salisbury, Wiltshire SP4 0JQ (GB). **OTSUKA PHARMACEUTICAL CO. LIMITED** [JP/JP]; 9, Kanda-Tsukasamachi 2-chome, Chiyoda-ku, Tokyo, 101-8535 (JP).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **MAIONE, Sabatino** [IT/IT]; The Second University of Naples, Via Constantinopoli 16, I-80138 Naples (IT). **ROSSI, Francesco** [IT/IT]; The Second University of Naples, Via Constantinopoli 16, I-80138 Naples (IT). **GUY, Geoffrey** [GB/GB]; GW Pharmaceuticals Limited, Porton Down Science Park, Salisbury SP4 0JQ (GB). **STOTT, Colin** [GB/GB]; GW Pharmaceuticals Limited, Porton Down Science Park, Salisbury SP4 0JQ (GB). **KIKUCHI, Tetsuro** [JP/JP]; Otsuka Pharmaceutical Co., Limited, 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka 5410045 (JP).

(74) Agent: **HARRISON GODDARD FOOTE**; 4th Floor, Merchant Exchange, 17-19 Whitworth Street West, Manchester M1 5WG (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

WO 2012/160358 A1

(54) **Title**: CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN

(57) **Abstract**: The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and / or purified from cannabis plant extracts.